{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:26:08Z","timestamp":1793676368695,"version":"4.5.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82394434"],"award-info":[{"award-number":["82394434"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing High level Innovative and Entrepreneurial Youth Top notch Talent Program","award":["G202522130"],"award-info":[{"award-number":["G202522130"]}]},{"name":"Xuanwu Hospital Talent Convergence Program","award":["HZ2025PYDTR006"],"award-info":[{"award-number":["HZ2025PYDTR006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00259-026-08140-6","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:08:00Z","timestamp":1789610880000},"page":"7955-7968","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cerebellar cortical amyloid deposition biases 18F-Florbetapir PET quantification with whole cerebellum as reference region"],"prefix":"10.1007","volume":"53","author":[{"given":"Meixi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-7930","authenticated-orcid":false,"given":"Shaozhen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"8140_CR1","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/d41586-026-00564-2","volume":"650","author":"R Fieldhouse","year":"2026","unstructured":"Fieldhouse R. China is waging war on Alzheimer\u2019s. What can its approach teach the rest of the world? Nature. 2026;650:816\u20138. https:\/\/doi.org\/10.1038\/d41586-026-00564-2.","journal-title":"Nature"},{"key":"8140_CR2","doi-asserted-by":"publisher","unstructured":"2025 Alzheimer's disease facts and figures. Alzheimer's Dement. 2025;21:e70235. https:\/\/doi.org\/10.1002\/alz.70235.","DOI":"10.1002\/alz.70235"},{"key":"8140_CR3","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.jalz.2017.01.018","volume":"13","author":"EC Mormino","year":"2017","unstructured":"Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, et al. Early and late change on the preclinical Alzheimer\u2019s cognitive composite in clinically normal older individuals with elevated amyloid \u03b2. Alzheimer\u2019s Dement. 2017;13:1004\u201312. https:\/\/doi.org\/10.1016\/j.jalz.2017.01.018.","journal-title":"Alzheimer's Dement"},{"key":"8140_CR4","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s Dement. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimer's Dement"},{"key":"8140_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer\u2019s Dement. 2015;11:1-15.e4. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","journal-title":"Alzheimer's Dement"},{"key":"8140_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CHv Dyck","year":"2023","unstructured":"Dyck CHv, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"8140_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic alzheimer disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"key":"8140_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMoa2308719","volume":"390","author":"AR Rezai","year":"2024","unstructured":"Rezai AR, D\u2019Haese P-F, Finomore V, Carpenter J, Ranjan M, Wilhelmsen K, et al. Ultrasound blood-brain barrier opening and Aducanumab in Alzheimer\u2019s Disease. N Engl J Med. 2024;390:55\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2308719.","journal-title":"N Engl J Med"},{"key":"8140_CR9","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.1002\/alz.14336","volume":"20","author":"LE Collij","year":"2024","unstructured":"Collij LE, Bollack A, Joie RL, Shekari M, Bullich S, Ro\u00e9-Vellv\u00e9 N, et al. Centiloid recommendations for clinical context-of-use from the AMYPAD consortium. Alzheimer\u2019s Dement. 2024;20:9037\u201348. https:\/\/doi.org\/10.1002\/alz.14336.","journal-title":"Alzheimer's Dement"},{"key":"8140_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.114.149732","volume":"56","author":"K Chen","year":"2015","unstructured":"Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-\u03b2 PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56:560\u20136. https:\/\/doi.org\/10.2967\/jnumed.114.149732.","journal-title":"J Nucl Med"},{"key":"8140_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.neuroimage.2014.11.055","volume":"108","author":"M Brendel","year":"2015","unstructured":"Brendel M, H\u00f6genauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage. 2015;108:450\u20139. https:\/\/doi.org\/10.1016\/j.neuroimage.2014.11.055.","journal-title":"Neuroimage"},{"key":"8140_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-016-0172-3","volume":"8","author":"S Shokouhi","year":"2016","unstructured":"Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, et al. Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment. Alzheimer\u2019s Res Ther. 2016;8:2. https:\/\/doi.org\/10.1186\/s13195-016-0172-3.","journal-title":"Alzheimer's Res Ther"},{"key":"8140_CR13","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s00259-017-3666-8","volume":"44","author":"J Blautzik","year":"2017","unstructured":"Blautzik J, Brendel M, Sauerbeck J, Kotz S, Scheiwein F, Bartenstein P, et al. Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden. Eur J Nucl Med Mol Imaging. 2017;44:1364\u201374. https:\/\/doi.org\/10.1007\/s00259-017-3666-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8140_CR14","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2967\/jnumed.116.187351","volume":"58","author":"S Bullich","year":"2017","unstructured":"Bullich S, Villemagne VL, Catafau AM, Jovalekic A, Koglin N, Rowe CC, et al. Optimal reference region to measure longitudinal Amyloid-\u03b2 change with 18F-Florbetaben PET. J Nucl Med. 2017;58:1300\u20136. https:\/\/doi.org\/10.2967\/jnumed.116.187351.","journal-title":"J Nucl Med"},{"key":"8140_CR15","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2967\/jnumed.117.204271","volume":"59","author":"VJ Lowe","year":"2018","unstructured":"Lowe VJ, Lundt ES, Senjem ML, Schwarz CG, Min H-K, Przybelski SA, et al. White matter reference region in PET Studies of 11C-Pittsburgh compound B uptake: effects of age and Amyloid-\u03b2 deposition. J Nucl Med. 2018;59:1583\u20139. https:\/\/doi.org\/10.2967\/jnumed.117.204271.","journal-title":"J Nucl Med"},{"key":"8140_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2967\/jnumed.118.209130","volume":"60","author":"P Chiao","year":"2019","unstructured":"Chiao P, Bedell BJ, Avants B, Zijdenbos AP, Grand\u2019Maison M, O\u2019Neill P, et al. Impact of reference and target region selection on Amyloid PET SUV ratios in the Phase 1b PRIME Study of Aducanumab. J Nucl Med. 2019;60:100\u20136. https:\/\/doi.org\/10.2967\/jnumed.118.209130.","journal-title":"J Nucl Med"},{"key":"8140_CR17","doi-asserted-by":"publisher","first-page":"14950","DOI":"10.1038\/s41598-020-70978-z","volume":"10","author":"SH Cho","year":"2020","unstructured":"Cho SH, Choe YS, Park S, Kim YJ, Kim HJ, Jang H, et al. Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid. Sci Rep. 2020;10:14950. https:\/\/doi.org\/10.1038\/s41598-020-70978-z.","journal-title":"Sci Rep"},{"key":"8140_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13550-020-00714-1","volume":"10","author":"F Heeman","year":"2020","unstructured":"Heeman F, Hendriks J, Alves IL, Ossenkoppele R, Tolboom N, Berckel BNMv, et al. [11C]PIB amyloid quantification: effect of reference region selection. EJNMMI Res. 2020;10:123. https:\/\/doi.org\/10.1186\/s13550-020-00714-1.","journal-title":"EJNMMI Res"},{"key":"8140_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.21037\/qims-20-110","volume":"11","author":"M Wang","year":"2021","unstructured":"Wang M, Yan Z, Zhang H, Lu J, Li L, Yu J, et al. Parametric estimation of reference signal intensity in the quantification of amyloid-beta deposition: an 18F-AV-45 study. Quant Imaging Med Surg. 2021;11:249\u201363. https:\/\/doi.org\/10.21037\/qims-20-110.","journal-title":"Quant Imaging Med Surg"},{"key":"8140_CR20","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1002\/alz.13883","volume":"20","author":"M Shekari","year":"2024","unstructured":"Shekari M, Garc\u00eda DV, Collij LE, Altomare D, Heeman F, Pemberton H, et al. Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology. Alzheimer\u2019s Dement. 2024;20:5102\u201313. https:\/\/doi.org\/10.1002\/alz.13883.","journal-title":"Alzheimer's Dement"},{"key":"8140_CR21","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/wnl.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, R\u00fcb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u2013800. https:\/\/doi.org\/10.1212\/wnl.58.12.1791.","journal-title":"Neurology"},{"key":"8140_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0006-8993(98)01279-7","volume":"818","author":"J Wegiel","year":"1999","unstructured":"Wegiel J, Wisniewski HM, Dziewiatkowski J, Badmajew E, Tarnawski M, Reisberg B, et al. Cerebellar atrophy in Alzheimer\u2019s disease-clinicopathological correlations. Brain Res. 1999;818:41\u201350. https:\/\/doi.org\/10.1016\/s0006-8993(98)01279-7.","journal-title":"Brain Res"},{"key":"8140_CR23","doi-asserted-by":"publisher","first-page":"102749","DOI":"10.1016\/j.nicl.2021.102749","volume":"31","author":"V Ghisays","year":"2021","unstructured":"Ghisays V, Lopera F, Goradia DD, Protas HD, Malek-Ahmadi MH, Chen Y, et al. PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer\u2019s disease-causing Presenilin-1 E280A mutation carriers. NeuroImage Clin. 2021;31:102749. https:\/\/doi.org\/10.1016\/j.nicl.2021.102749.","journal-title":"NeuroImage Clin"},{"key":"8140_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-025-02198-3","volume":"14","author":"J Yu","year":"2025","unstructured":"Yu J, Woodworth DC, Fletcher E, Greenia DE, Bukhari S, Montine TJ, et al. Amyloid quantification in the oldest-old: selecting regions for optimizing correspondence between postmortem pathology and amyloid PET. Acta Neuropathol Commun. 2025;14:7. https:\/\/doi.org\/10.1186\/s40478-025-02198-3.","journal-title":"Acta Neuropathol Commun"},{"key":"8140_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimer's Dement"},{"key":"8140_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimer's Dement"},{"key":"8140_CR27","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/alz.12316","volume":"17","author":"O Hansson","year":"2021","unstructured":"Hansson O, Batrla R, Brix B, Carrillo MC, Corradini V, Edelmayer RM, et al. The Alzheimer\u2019s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau. Alzheimer\u2019s Dement. 2021;17:1575\u201382. https:\/\/doi.org\/10.1002\/alz.12316.","journal-title":"Alzheimer's Dement"},{"key":"8140_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","volume":"11","author":"MJ Leit\u00e3o","year":"2019","unstructured":"Leit\u00e3o MJ, Silva-Sp\u00ednola A, Santana I, Olmedo V, Nadal A, Bastard NL, et al. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2019;11:91. https:\/\/doi.org\/10.1186\/s13195-019-0550-8.","journal-title":"Alzheimer's Res Ther"},{"key":"8140_CR29","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1007\/s00259-020-04752-8","volume":"47","author":"S Yan","year":"2020","unstructured":"Yan S, Zheng C, Cui B, Qi Z, Zhao Z, An Y, et al. Multiparametric imaging hippocampal neurodegeneration and functional connectivity with simultaneous PET\/MRI in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2020;47:2440\u201352. https:\/\/doi.org\/10.1007\/s00259-020-04752-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8140_CR30","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1093\/brain\/awab160","volume":"144","author":"S Yan","year":"2021","unstructured":"Yan S, Zheng C, Paranjpe MD, Li Y, Li W, Wang X, et al. Sex modifies APOE \u03b54 dose effect on brain tau deposition in cognitively impaired individuals. Brain. 2021;144:3201\u201311. https:\/\/doi.org\/10.1093\/brain\/awab160.","journal-title":"Brain"},{"key":"8140_CR31","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00259-025-07485-8","volume":"53","author":"S Bi","year":"2026","unstructured":"Bi S, Chen Z, Li Y, Cui B, Shan Y, Yang H, et al. Glucose metabolism alterations and A\u03b2 deposition in AD and FTD are related to the distribution of neurotransmitter systems. Eur J Nucl Med Mol Imaging. 2026;53:1169\u201382. https:\/\/doi.org\/10.1007\/s00259-025-07485-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8140_CR32","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.neuroimage.2007.10.038","volume":"39","author":"J Tohka","year":"2008","unstructured":"Tohka J, Reilhac A. Deconvolution-based partial volume correction in Raclopride-PET and Monte Carlo comparison to MR-based method. Neuroimage. 2008;39:1570\u201384. https:\/\/doi.org\/10.1016\/j.neuroimage.2007.10.038.","journal-title":"Neuroimage"},{"key":"8140_CR33","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.7150\/thno.35366","volume":"9","author":"M Liu","year":"2019","unstructured":"Liu M, Paranjpe MD, Zhou X, Duy PQ, Goyal MS, Benzinger TLS, et al. Sex modulates the ApoE \u03b54 effect on brain tau deposition measured by 18F-AV-1451 PET in individuals with mild cognitive impairment. Theranostics. 2019;9:4959\u201370. https:\/\/doi.org\/10.7150\/thno.35366.","journal-title":"Theranostics"},{"key":"8140_CR34","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.neuroimage.2007.12.035","volume":"40","author":"S Mori","year":"2008","unstructured":"Mori S, Oishi K, Jiang H, Jiang L, Li X, Akhter K, et al. Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage. 2008;40:570\u201382. https:\/\/doi.org\/10.1016\/j.neuroimage.2007.12.035.","journal-title":"Neuroimage"},{"key":"8140_CR35","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00259-021-05195-5","volume":"48","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, Grothe MJ, Sch\u00f6ll M, Initiative AsDN. Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter. Eur J Nucl Med Mol Imaging. 2021;48:2283\u201394. https:\/\/doi.org\/10.1007\/s00259-021-05195-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8140_CR36","doi-asserted-by":"publisher","first-page":"e209665","DOI":"10.1212\/wnl.0000000000209665","volume":"103","author":"J Wang","year":"2024","unstructured":"Wang J, Ackley S, Woodworth DC, Sajjadi SA, Decarli CS, Fletcher EF, et al. Associations of Amyloid Burden, White Matter Hyperintensities, and Hippocampal Volume With Cognitive Trajectories in the 90+ Study. Neurology. 2024;103:e209665. https:\/\/doi.org\/10.1212\/wnl.0000000000209665.","journal-title":"Neurology"},{"key":"8140_CR37","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","volume":"14","author":"M Navitsky","year":"2018","unstructured":"Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimer\u2019s Dement. 2018;14:1565\u201371. https:\/\/doi.org\/10.1016\/j.jalz.2018.06.1353.","journal-title":"Alzheimer's Dement"},{"key":"8140_CR38","doi-asserted-by":"publisher","first-page":"e12434","DOI":"10.1002\/dad2.12434","volume":"15","author":"W Coath","year":"2023","unstructured":"Coath W, Modat M, Cardoso MJ, Markiewicz PJ, Lane CA, Parker TD, et al. Operationalizing the centiloid scale for [18F]florbetapir PET studies on PET\/MRI. Alzheimers Dement (Amst). 2023;15:e12434. https:\/\/doi.org\/10.1002\/dad2.12434.","journal-title":"Alzheimers Dement (Amst)"},{"key":"8140_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13195-026-02071-y","volume":"18","author":"H Xue","year":"2026","unstructured":"Xue H, Bi S, Wang M, Zhu X, Wang F, Wang Y, et al. Optimizing cutoffs for clinical interpretation of brain amyloid status using PET\/MRI: a multisite study. Alzheimers Res Ther. 2026;18:172. https:\/\/doi.org\/10.1186\/s13195-026-02071-y","journal-title":"Alzheimer's Res Ther"},{"key":"8140_CR40","doi-asserted-by":"publisher","unstructured":"Rousselet GA, Pernet CR, Wilcox RR. The Percentile Bootstrap: A primer with step-by-step instructions in R. Adv Methods Pract Psychol Sci. 2021;4. https:\/\/doi.org\/10.1177\/2515245920911881.","DOI":"10.1177\/2515245920911881"},{"key":"8140_CR41","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.2967\/jnumed.115.171652","volume":"57","author":"AM Catafau","year":"2016","unstructured":"Catafau AM, Bullich S, Seibyl JP, Barthel H, Ghetti B, Leverenz J, et al. Cerebellar Amyloid-\u03b2 Plaques: How frequent are they, and do they influence 18F-Florbetaben SUV Ratios? J Nucl Med. 2016;57:1740\u20135. https:\/\/doi.org\/10.2967\/jnumed.115.171652.","journal-title":"J Nucl Med"},{"key":"8140_CR42","doi-asserted-by":"publisher","first-page":"9256","DOI":"10.3390\/ijms23169256","volume":"23","author":"MA Coto-Vilcapoma","year":"2022","unstructured":"Coto-Vilcapoma MA, Castilla-Silgado J, Fern\u00e1ndez-Garc\u00eda B, Pinto-Hern\u00e1ndez P, Cipriani R, Capetillo-Zarate E, et al. New, fully implantable device for selective clearance of CSF-target molecules: proof of concept in a murine model of Alzheimer\u2019s Disease. Int J Mol Sci. 2022;23:9256. https:\/\/doi.org\/10.3390\/ijms23169256.","journal-title":"Int J Mol Sci"},{"key":"8140_CR43","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367:795\u2013804. https:\/\/doi.org\/10.1056\/NEJMoa1202753.","journal-title":"N Engl J Med"},{"key":"8140_CR44","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00259-019-04461-x","volume":"47","author":"C Bastin","year":"2020","unstructured":"Bastin C, Bahri MA, Meyer F, Manard M, Delhaye E, Plenevaux A, et al. In vivo imaging of synaptic loss in Alzheimer\u2019s disease with [18F]UCB-H positron emission tomography. Eur J Nucl Med Mol Imaging. 2020;47:390\u2013402. https:\/\/doi.org\/10.1007\/s00259-019-04461-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8140_CR45","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/alz.12097","volume":"16","author":"AP Mecca","year":"2020","unstructured":"Mecca AP, Chen M-K, O\u2019Dell RS, Naganawa M, Toyonaga T, Godek TA, et al. In vivo measurement of widespread synaptic loss in Alzheimer\u2019s disease with SV2A PET. Alzheimer\u2019s Dement. 2020;16:974\u201382. https:\/\/doi.org\/10.1002\/alz.12097.","journal-title":"Alzheimer's Dement"},{"key":"8140_CR46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.neurobiolaging.2023.08.001","volume":"132","author":"S Moallemian","year":"2023","unstructured":"Moallemian S, Salmon E, Bahri MA, Beliy N, Delhaye E, Balteau E, et al. Multimodal imaging of microstructural cerebral alterations and loss of synaptic density in Alzheimer\u2019s disease. Neurobiol Aging. 2023;132:24\u201335. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2023.08.001.","journal-title":"Neurobiol Aging"},{"key":"8140_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1017\/s1092852900027000","volume":"13","author":"MA Mintun","year":"2008","unstructured":"Mintun MA. FDG and amyloid positron emission tomography. CNS Spectr. 2008;13:21\u20134. https:\/\/doi.org\/10.1017\/s1092852900027000.","journal-title":"CNS Spectr"},{"key":"8140_CR48","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s00259-016-3353-1","volume":"43","author":"S Tiepolt","year":"2016","unstructured":"Tiepolt S, Hesse S, Patt M, Luthardt J, Schroeter ML, Hoffmann K-T, et al. Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2016;43:1700\u20139. https:\/\/doi.org\/10.1007\/s00259-016-3353-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8140_CR49","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s12149-023-01843-y","volume":"37","author":"T Tada","year":"2023","unstructured":"Tada T, Hara K, Fujita N, Ito Y, Yamaguchi H, Ohdake R, et al. Comparative examination of the pons and corpus callosum as reference regions for quantitative evaluation in positron emission tomography imaging for Alzheimer\u2019s disease using 11C-Pittsburgh Compound-B. Ann Nucl Med. 2023;37:410\u20138. https:\/\/doi.org\/10.1007\/s12149-023-01843-y.","journal-title":"Ann Nucl Med"},{"key":"8140_CR50","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2967\/jnumed.114.148981","volume":"56","author":"SM Landau","year":"2015","unstructured":"Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal \u03b2-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56:567\u201374. https:\/\/doi.org\/10.2967\/jnumed.114.148981.","journal-title":"J Nucl Med"},{"key":"8140_CR51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/jnen\/nlad107","volume":"83","author":"G Lopez","year":"2024","unstructured":"Lopez G, Magaki SD, Williams CK, Paganini-Hill A, Vinters HV. Characterization of cerebellar amyloid-\u03b2 deposits in Alzheimer disease. J Neuropathol Exp Neurol. 2024;83:72\u20138. https:\/\/doi.org\/10.1093\/jnen\/nlad107.","journal-title":"J Neuropathol Exp Neurol"},{"key":"8140_CR52","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1007\/s12035-024-04543-4","volume":"62","author":"ZL Almeida","year":"2025","unstructured":"Almeida ZL, Vaz DC, Brito RMM. Morphological and Molecular Profiling of Amyloid-\u03b2 Species in Alzheimer\u2019s Pathogenesis. Mol Neurobiol. 2025;62:4391\u2013419. https:\/\/doi.org\/10.1007\/s12035-024-04543-4.","journal-title":"Mol Neurobiol"},{"key":"8140_CR53","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JAR Nicoll","year":"2003","unstructured":"Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448\u201352. https:\/\/doi.org\/10.1038\/nm840.","journal-title":"Nat Med"},{"key":"8140_CR54","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41591-025-03574-1","volume":"31","author":"L Olst","year":"2025","unstructured":"Olst L, Simonton B, Edwards AJ, Forsyth AV, Boles J, Jamshidi P, et al. Microglial mechanisms drive amyloid-\u03b2 clearance in immunized patients with Alzheimer\u2019s disease. Nat Med. 2025;31:1604\u201316. https:\/\/doi.org\/10.1038\/s41591-025-03574-1.","journal-title":"Nat Med"},{"key":"8140_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nbd.2003.09.015","volume":"15","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis. 2004;15:11\u201320. https:\/\/doi.org\/10.1016\/j.nbd.2003.09.015.","journal-title":"Neurobiol Dis"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08140-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08140-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08140-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:44Z","timestamp":1793672984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08140-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":55,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["8140"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08140-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"17 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Capital Medical University (No. [2024] 131-001).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the parents.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}